Condition: Multiple Myeloma · Sponsor: Karyopharm Therapeutics Inc
This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: * Arm 1: Selinexor + dexamethasone + pomalidomide (SPd); enrollment complete * Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete * Arm 3: Selinexor + dexamethasone + lenalidomide (SRd) in RRMM; enrollment complete * Arm 4: Selinexor + dexamethasone + pomalidomide + bortezomib (SPVd); enrollment complete * Arm 5: Selinexor + dexamethasone + daratumumab (SDd); enrollment complete * Arm 6: Selinexor + dexamethasone + carfilzomib (SKd); enrollment complete * Arm 7: Selinexor + dexamethasone + lenalidomide (SRd) in NDMM; enrollment complete * Arm 8: Selinexor + dexamethasone + ixazomib (SNd); enrollment complete * Arm 9: Selinexor + dexamethasone + pomalidomide + elotuzumab (SPEd); enrollment complete * Arm 10: Selinexor + dexamethasone + belantamab mafodotin (SBd); enrollment complete * Arm 11: Selinexor + dexamethasone + pomalidomide + daratumumab (SDPd); enrollment complete * Arm 12: Selinexor + dexamethasone + mezigdomide (SMd); actively recruiting Selinexor pharmacokinetics: * PK Run-in (Days 1-14): Starting in protocol version 8.0, patients enrolled to any arm in the Dose Escalation Phase (i.e., Arm 4 \[SPVd\], Arm 6 \[SKd\], Arm 8 \[SNd\…
This description comes directly from the study's public registry record.
Karyopharm Medical Information · (888) 209-9326 · clinicaltrials@karyopharm.com
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | Active Not Recruiting |
| Jonnsson Comprehensive Cancer Center / University of Los Angeles | Los Angeles, California, United States | Active Not Recruiting |
| Sarah Cannon-Colorado Blood Cancer Institute | Denver, Colorado, United States | Withdrawn |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Completed |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | Completed |
| Hackensack University Medical Center - John Theurer Cancer Center | Hackensack, New Jersey, United States | Active Not Recruiting |
| Columbia University | New York, New York, United States | Completed |
| Weill Cornell Medicine | New York, New York, United States | Completed |
| Wilmot Cancer Center/ University of Rochester | Rochester, New York, United States | Active Not Recruiting |
| University of North Carolina - Chapel Hill Comprehensive Cancer Center | Chapel Hill, North Carolina, United States | Active Not Recruiting |
| Duke Institute of Cancer/ Duke University | Durham, North Carolina, United States | Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02343042